Effects of pertussis vaccination on disease: Vaccine efficacy in reducing clinical severity

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 772-779

  Préziosi, Marie Pierre ^a,b   Halloran, M Elizabeth ^b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE;

ANAMNESIS; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; PERTUSSIS VACCINE; SENEGAL; WHOOPING COUGH;

EID: 0141676176     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377270     Document Type: Article

References (29)

1. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 1989; 115:686-93.
2. Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Pediatr Infect Dis J 1995; 14:870-4.
3. Chin J. Pertussis, parapertussis (whooping cough). In: Chin J, ed. Control of communicable diseases manual. 17th ed. Washington, DC: American Public Health Association, 2000:375-9.
4. Kendrick PL, Eldering G, Borowski A. A study in active immunization against pertussis. Am J Hyg 1939; 29:133-53.
5. Medical Research Council. The prevention of whooping-cough by vaccination: a Medical Research Council investigation. BMJ 1951;i:1463-71.
6. Grob PR, Crowder MJ, Robbins JF. Effect of vaccination on severity and dissemination of whooping cough. Br Med J (Clin Res Ed) 1981;282:1925-8.
7. Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990; 8:457-61.
8. Long SS, Welkon CJ, Clark JL. Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 1990; 161:480-6.
9. Gordon M, Davies HD, Gold R. Clinical and microbiologic features of children presenting with pertussis to a Canadian pediatric hospital during an eleven-year period. Pediatr Infect Dis J 1994; 13:617-22.
10. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 1994; 169:1297-305.
11. White JM, Fairley CK, Owen D, Matthews RC, Miller E. The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun Dis Rep CDR Rev 1996; 6:R86-91.
12. Halloran ME, Longini IMJ, Struchiner CJ. Design and interpretation of vaccine field studies. Epidemiol Rev 1999; 21:73-88.
13. Delaunay V, ed. La situation demographique et epidemiologique dans la zone de Niakhar au Senegal, 1984-1996. Rapport Collectif. Dakar: ORSTOM, 1998.
14. Garenne M, Cantrelle P. Three decades of research on population and health: the Orstom experience in rural Senegal, 1962-1991. In: Das Gupta M, Aaby P, Garenne M, Pison G, eds. Prospective community studies in developing countries (International Studies in Demography). Oxford: Clarendon Press, 1998:233-52.
15. Simondon F, Préziosi M-P, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606-12.
16. Préziosi M-P, Yam A, Ndiaye M, Simaga A, Simondon F, Wassilak SG. Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. N Engl J Med 1997; 336:370-3.
17. Préziosi M-P, Yam A, Wassilak SG, et al. Epidemiology of whooping cough in a West African community before and after introduction of a widespread vaccination programme. Am J Epidemiol 2002; 155:891-6.
18. Aaby P, Samb B, Simondon F, et al. Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal. Am J Epidemiol 1993; 138:746-55.
19. Simondon F, Iteman I, Préziosi M-P, Yam A, Guiso N. Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 1998; 5:130-4.
20. Halloran ME, Préziosi M-P, Chu H. Estimating vaccine efficacy from secondary attack rates. JASA 2003; 98:38-46.
21. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
22. Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics 1978; 34:469-74.
23. Nielsen NM, Hedegaard K, Aaby P. Intensity of exposure and severity of whooping cough. J Infect 2001; 43:177-81.
24. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical score for severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67.
25. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955-60.
26. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 1996; 334:341-8.
27. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55.
28. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101:1-11.
29. Chang MN, Guess HA, Heyse JF. Reduction in burden of illness: a new efficacy measure for prevention trials. Stat Med 1994; 13:1807-14.